Idiopathic hypersomnia is a neurological sleep disorder characterized by excessive daytime sleepiness and long periods of sleep that does not improve even after long sleep. The treatment of idiopathic hypersomnia is done through medication and behavioral therapies. Medications like psychostimulants, serotonin modulators, wakefulness promoting agents are used to treat the condition and increase wakefulness. The increasing prevalence of idiopathic hypersomnia due to genetic and environmental factors is expected to drive the growth of the idiopathic hypersomnia treatment market.
The Global Idiopathic Hypersomnia Treatment Market is estimated to be valued at US$ 389.86 Mn in 2024 and is expected to exhibit a CAGR of 7.3% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Idiopathic Hypersomnia Treatment Market are Esaote SPA, Epica Animal Health, IDEXX Laboratories, Carestream Health, IMV Imaging, Fujifilm Holdings Corp., Hallmarq Veterinary Imaging, and Canon Medical Systems Corporation, among others. The companies are involved in developing and commercialization of new drugs and diagnostic tools to increase their market share.
The increasing awareness and diagnosis of idiopathic hypersomnia presents a major opportunity for players in the market. Aggressive marketing campaigns by pharmaceutical companies are expected to spread more awareness among physicians and patients about the treatment options available.
The key players are expanding their geographical reach through collaborations and partnerships with regional players. Companies are also focusing on emerging markets in Asia Pacific and Latin America owing to high growth potential due to increasing healthcare investments in these regions.
Market drivers and restrain
The increasing awareness and definitive diagnosis of Idiopathic Hypersomnia Treatments Market Demand as a medical condition is a key market driver. The approval and commercialization of new wakefulness promoting agents and other treatment options is also boosting the market growth. However, the lack of approved treatments for long term management of Idiopathic hypersomnia is a major challenge. Existing medications also have tolerability issues and side effects which limit their use. High cost of treatment especially in developing countries also restraints the market potential in those regions.
Segment Analysis
The idiopathic hypersomnia treatment market is dominated by the idiopathic hypersomnia drugs sub segment. This is because idiopathic hypersomnia is primarily treated through prescription medications. The key drugs prescribed are Schedule IV controlled substances such as modafinil and armodafinil which help promote wakefulness. Recently, sodium oxybate (Xyrem) has also emerged as an effective therapeutic option, especially for patients experiencing long sleep times and frequently feeling unrefreshed despite long periods of sleep. Its usage has grown steadily owing to its dual mode of action on enhancing REM and non-REM sleep.
Global Analysis
In terms of regional analysis, the North America idiopathic hypersomnia treatment market holds the largest revenue share presently and is expected to maintain its dominance over the forecast period. This is attributed to growing awareness about the condition aided by presence of leading healthcare providers and availability of advanced treatment facilities here. Meanwhile, Asia Pacific region is exhibiting fastest growth and is estimated to become the most lucrative market by 2027. Rising healthcare expenditure, expanding patient pool afflicted with the disorder and improving access to diagnosis and medications are propelling the Asia Pacific market.
Get more insights on Idiopathic Hypersomnia Treatment Market
Also read related article on Global Sleep App Market
Comments
0 comment